⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477228 | 0.94 | — | — | |
| SCHEMBL9727085 | 0.92 | HTT (0.52) | — | |
| Hydrochloric Acid SCHEMBL11600093 | 0.92 | HTT (0.47) | — | |
| SCHEMBL34638 | 0.92 | HTT (0.52) | — | |
| Hydrochloric Acid SCHEMBL8939931 | 0.89 | HTT (0.50) | — | |
| Benzene SCHEMBL3841909 | 0.89 | HTT (0.55) | — | |
| SCHEMBL4615811 | 0.88 | — | — | |
| Benzene SCHEMBL8030551 | 0.87 | HTT (0.59) | — | |
| Pyrrolidine SCHEMBL25184622 | 0.81 | HTT (0.40) | — | |
| SCHEMBL18124344 | 0.81 | HTT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025074305-A1 | N-(1-(AMINOMETHYL)CYCLOPROPYL)(ARYL OR HETEROARYL) CARBOXAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-10 | — | — | WO | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |